Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: J07BB02Conditional Approval

Arepanrix(split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs.)

Influenza, Human;Immunization;Disease Outbreaks

Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.

EMA Authorisation: 23/03/2010

INN: pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)

Indication

Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Arepanrix — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about ArepanrixCreate Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.